Ralph E Buttyan

6451532, Sep 17, 2002

Oct 15, 1999

09/403145

James M. McKiernan - New York NY
Ihor S. Sawczuk - Tenafly NJ
Ralph Buttyan - New York NY
Neil H. Bander - Chappaqua NY

The Trustees of Columbia University in the City of New York - New York NY
Cornell Research Foundation, Inc. - Ithaca NY

C12Q 168

435 6, 435 911, 435 912

This invention provides methods of: (a) diagnosing; (b) determining the stage of; and (c) monitoring the effect of a therapeutic intervention for a renal cell carcinoma in a human subject which comprises detecting the expression of the MN gene. In one embodiment, the method is directed to detection of the renal cell carcinoma known as clear cell carcinoma. In another embodiment, the method is used as a peripheral blood assay. In another embodiment, the method is a polymerase chain reaction assay for amplifying and detecting the presence of the cDNA molecule encoding the MN protein.

20070248535, Oct 25, 2007

Feb 7, 2006

11/349473

Ralph Buttyan - New York NY, US
Mitchell Benson - New York NY, US
Min-Wei Chen - Flushing NY, US
Francis Vacherot - Creteil, FR
Luis Carlos Soares Queires - Salvador, BR
Stephane Terry - Creteil, FR
Alexandre De La Taille - Paris, FR
Sixtina Gil Diez De Medina - Paris, FR

THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK - New York NY
INSERM - Paris

A61K 51/00
A01K 67/00
A61K 31/7052
C07H 21/00
C12N 1/00
C12Q 1/68
G01N 33/53
C12N 5/00
C07K 16/00
A61K 38/00
A61K 39/395

424001490, 424001110, 424001690, 424001730, 424130100, 424009100, 435243000, 435325000, 435410000, 435006000, 435007100, 514001000, 514002000, 514044000, 530387900, 530388100, 536023100, 800013000, 800014000, 800015000, 800017000, 800018000, 800003000

The invention is directed to compounds and methods for treating or preventing hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity, including antisense oligonucleotides and antibodies. The invention also provides for the use of protocadherin-PC as an in vivo prostate cancer biomarker, and includes a kit for detecting prostate cancer in biological samples. Also covered by the invention is a transgenic non-human mammal engineered to overexpress protocadherin-PC specifically in the prostate.

20090311716, Dec 17, 2009

Aug 17, 2009

12/542231

Ralph BUTTYAN - New York NY, US
Mitchell C. BENSON - New York NY, US
Min-Wei CHEN - Flushing NY, US
Francis VACHEROT - Creteil, FR
Luis Carlos SOARES QUEIRES - Salvador, BR
Stephane TERRY - Creteil, FR
Alexandre DE LA TAILLE - Paris, FR
Sixtina GIL DIEZ DE MEDINA - Paris, FR

THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK - New York NY

G01N 33/53

435 71

The invention is directed to compounds and methods for treating or preventing hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity, including antisense oligonucleotides and antibodies. The invention also provides for the use of protocadherin-PC as an in vivo prostate cancer biomarker, and includes a kit for detecting prostate cancer in biological samples. Also covered by the invention is a transgenic non-human mammal engineered to overexpress protocadherin-PC specifically in the prostate.

58404945, Nov 24, 1998

Apr 18, 1997

8/844024

Aaron E. Katz - Armonk NY
Ralph Buttyan - New York NY
Anthony Raffo - New York NY
Carl A. Olsson - Larchmont NY

The Trustees of Columbia University in the City of New York - New York NY

C12Q 168
C07H 2104
C12P 1934

435 6

This invention provides a method of determining the stage of prostate cancer in a human subject using a sample of peripheral blood from a human subject. The invention uses reverse transcriptase-PCR to detect the mRNA encoding prostate specific antigen (PSA) in circulating cells expressing PSA. The invention further uses digoxigenin enhancement of the resultant cDNA signal. The method has an overall sensitivity capable of detecting one PSA expressing cell per 100,000 cells. The method produced no false positives and had a superior detection selectivity for patients with nonlocalized prostate cancer.

59767944, Nov 2, 1999

Jan 13, 1997

8/718547

Aaron E. Katz - Armonk NY
Ralph Buttyan - New York NY
Anthony Raffo - New York NY
Carl A. Olsson - Larchmont NY

The Trustees of Columbia University in the City of New York - New York NY

C12Q 168
C12P 1934
C07H 2104

435 6

A method for enhancing the detection of prostate specific antigen in a biological sample comprising (a) extracting mRNA from the sample: (b) contacting the mRNA from step (a) with reverse transcriptase under conditions allowing for the production of cDNA; (c) contacting the cDNA from step (b) with a pair of reverse transcriptase polymerase chain reaction primers capable of specifically hybridizing with DNA encoding prostate specific antigen wherein one such primer is an oligonucleotide of 12 to 30 nucleotides in length and comprises the sequence 5-CACCCATCCTA-3' and wherein the second such primer is an oligonucleotide of 12 to 30 nucleotides in length and comprises the sequence 5'-TCCAGCCACGAC-3'; and wherein at least one of the primers is covalently linked to a modified digoxigenin molecule and under conditions allowing for extension of the primers; and (d) detecting the resulting amplified DNA.

60870982, Jul 11, 2000

Apr 15, 1997

8/839698

James M. McKiernan - Teaneck NJ
Ihor S. Sawczuk - Tenafly NJ
Ralph Buttyan - New York NY
Neil H. Bander - Chappaqua NY

The Trustees of Columbia University in the City of New York - New York NY
Cornell Research Foundation, Inc. - Ithaca NY

C12Q 168
C12P 1934
C07H 2104

435 6

This invention provides methods of (a) diagnosing; (b) determining the stage of; and (c) monitoring the effect of a therapeutic intervention for a renal cell carcinoma in a human subject which comprises detecting the expression of the MN gene. In one embodiment, the method is directed to detection of the renal cell carcinoma known as clear cell carcinoma. In another embodiment, the method is used as a peripheral blood assay. In another embodiment, the method is a polymerase chain reaction assay for amplifying and detecting the presence of the cDNA molecule encoding the MN protein.